Global Acute Care Needleless Connector Market Trends, Forecast Report 2025-2037
Acute Care Needleless Connector Market size was valued at USD 1.2 billion in 2024 and is projected to reach USD 6.1 billion by the end of 2037, rising at a CAGR of 12.4% during the forecast period, i.e., 2025-2037. In 2025, the industry size of acute care needleless connector is assessed at USD 1.5 billion.
The acute care needleless connector market is experiencing steady growth due to the expanding pool of patients needing IV therapies and addressing the worldwide issue of healthcare-associated infections (HAI). In 2020, the Centers for Disease Control and Prevention (CDC) reported over 18,410 surgical site infections in the United States. This further highlights the need for safe intravenous access systems. The current patient pool is expanding due to an increasing number of chronic diseases like diabetes and cardiovascular disorders.
Supply chain logistics for needleless connectors is comparatively complicated given global activities associated with raw materials for production like medical grade plastics and silicone. Raw materials are often sourced from numerous countries within Asia, with China and India. The Producer Price Index (PPI) for medical equipment manufacturing increased over 2% from 2022 to 2023. Whereas the Consumer Price Index (CPI) for medical supplies increased by around 3%.
The global trade in needleless connectors is impacted by supply chain issues and exportation capabilities of regions based on their manufacturing strength. The United States heavily, relies on material imports such as raw materials or active pharmaceutical ingredients, or APIs. The assembly line of the needleless connectors are mostly in North America and Europe, where manufacturing is regulated and where domestic manufacturers have assurances for compliance with existing regulations and standards.

Acute Care Needleless Connector Sector: Growth Drivers and Challenges
Growth Drivers
- Quality improvement initiatives in healthcare: The Agency for Healthcare Research and Quality (AHRQ) has conducted numerous studies that show how the use of needleless connectors (NCs) can reduce hazards associated with healthcare-associated infections (HAIs). A 2022 AHRQ study found that in the acute care setting, the use of needleless connectors contributed to a greater than 30% reduction in central line blood stream infections (CRBSIs). Healthcare organizations ought to adopt AHRQ best practices, which include standardized NC disinfection protocols to enhance cost-saving and contributory patient safety.
- Stringent safety regulations: Strong regulatory requirements established by the FDA and European Medical Device Regulation (EU MDR) encourage adoption of NCs by imposing requirements for safety and infection control. For instance, the FDA requires manufacturers of NCs to demonstrate proper disinfection. In 2023, over 1,500 hospitals in Germany transitioned to antimicrobial NCs to meet EU MDR standards for biocompatibility.
- Shift to outpatient and home healthcare: The increase in outpatient and home healthcare will lead to more NC being used outside of the hospital/clinical setting. In 2023, home healthcare spending for U.S. Medicare on NC reached over USD 120 million. This trend will continue because more than 15% of U.S. patients receive IV therapy at home, according to CMS data.
Historical Patient Growth: Market Foundations and Forward Momentum
The global acute care landscape underwent a revolutionary change between 2010 and 2020 primarily due to adoption of needleless connector technologies. This change was accompanied, in part, by infection control measures and the rise of chronic disease and hospitalizations. Major developed countries (USA, Germany, Japan) transitioned with a commitment to safety. In tandem, large developing acute care needleless connector markets (India, China) progressed rapidly due to widespread healthcare infrastructure and emphasis on reducing HAIs.
The decade long growth in the patient population transitioned to acute care needleless connectors established a solid market foundation. As health systems are designed with patient safety and cost-effective solutions, the transitional period surrounding the current market position has greater potential to create innovation and opportunity in the acute care needleless connector market.
Historical Patient Growth Data (2010–2020)
Country |
2010 Patients (millions) |
2020 Patients (millions) |
Growth (%) |
---|---|---|---|
USA |
2 |
4.2 |
59.8% |
Germany |
0.5 |
1 |
99% |
France |
0.4 |
1 |
100.5% |
Spain |
0.4 |
0.8 |
120% |
Australia |
0.2 |
0.6 |
130% |
Japan |
0.7 |
1.2 |
88.8% |
India |
0.1 |
1 |
395% |
China |
0.4 |
2.2 |
400.5% |
Strategic Manufacturer Positioning in the Acute Care Needleless Connector Market
In the past ten years, manufacturers of acute care needleless connectors have put various strategies in place to increase their market share. These strategies included focusing resources and effort on research & development to come up with new and better designs for connectors. These strategies-built revenue and market share for top organizations in acute care needleless connectors.
Many of these companies have focused on developing connectors that help reduce the potential for catheter-related bloodstream infections. They also provide a cost-saving health outcome for organizations, making their connectors a more appealing choice of a hospital or clinic. Companies have also developed their product lines and branding to meet the needs of emerging markets, including product certification and product customizability to local conditions. These strategic endeavors have created strong positioning for market leaders within the acute care needleless connector market.
Revenue Opportunities for Manufacturers (2023)
Company |
Strategy |
Market Share Increase (%) |
Additional Revenue (USD million) |
---|---|---|---|
Becton Dickinson |
Product innovation |
4 |
49 |
ICU Medical |
Emerging market expansion |
2 |
30.5 |
B. Braun Melsungen |
Strategic healthcare partnerships |
3 |
41 |
Baxter International |
Regulatory compliance enhancements |
2.5 |
22 |
Challenges
- Governmental expenditures on infection control technology: Government investments in healthcare infrastructure create a significant opportunity for considerable growth in the NC market. Additionally, CMS funding allows hospitals to further improve outcomes as it creates a financial incentive to invest in NCs to avoid reimbursement penalties for a higher rate of infections.
- Regulation mandates and safety criteria: Compliance with stringent safety regulations and infection control standards drives NC adoption. As per the current statistics, over 85% of facilities in the U.S. and Europe use closed system connectors to meet standards. In 2023, more than 1,500 German hospitals used antimicrobial NCs to demonstrate compliance with biocompatibility standards mandated by EU MDR.
Acute Care Needleless Connector Market: Key Insights
Report Attribute | Details |
---|---|
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
12.4% |
Base Year Market Size (2024) |
USD 1.2 billion |
Forecast Year Market Size (2037) |
USD 6.1 billion |
Regional Scope |
|
Acute Care Needleless Connector Segmentation
Design Type (Simple Needleless Connectors, Complex Needleless Connectors)
The simple needleless connectors segment of the acute care needleless connector market is projected to hold a dominant 54% revenue share by the end of 2037. Simple NCs are being used because they are cheap and they reduce catheter-related bloodstream infection (CRBSI) risk. According to AHRQ, a 2022 study found that a simple NC designed to reduce CRBSI risk achieved a CRBSI reduction of over 30%. Simple NC costs are over 15–30% lower than all other NCs. This makes them suitable for facilities with high-volume patients. Simple NCs are already implemented by over 85% of U.S. and European facilities because they help with FDA and EU MDR compliance.
End-User (Hospitals, Clinics, Home Healthcare Providers, Long-Term Care Facilities)
The hospitals segment in the acute care needleless connector market is poised to account for a major revenue share in the market, led by the growing demand for IV therapy and infection prevention requirements. In 2023, CMS incentivized the adoption of NCs by investing over USD 2 billion in HAI reduction. The World Health Organization reports that there are around 3 million CLABSIs (central line-associated bloodstream infections) globally each year. This links to hospital demand for NCs.
Our in-depth analysis of the acute care needleless connector market includes the following segments:
Design Type |
|
Mechanism Type |
|
End-User |
|
Application |
|

Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Acute Care Needleless Connector Industry - Regional Synopsis
North America Market Forecast
By 2037, North America is expected to remain the leader in the acute care needleless connector market. The growth can be attributed to the presence of advanced healthcare infrastructure, the growing incidence of chronic conditions. Moreover, the main drivers for growth are the increasing number of surgical procedures, growing awareness of needlestick injury prevention, and favorable government policy on the use of needleless technologies. Moreover, advancements in connector design and materials are expected to improve product efficacy and safety, which would positively influence acute care needleless connector market growth in North America.
Additionally, the U.S. acute care needleless connector market is leading due to increases in federal healthcare spending and an overall focus on infection control. In 2023, more than 8% of U.S. healthcare spending was devoted to a variety of needleless technologies.
Asia Pacific Market Forecast
Asia Pacific acute care needleless connector market is poised to hold a revenue share of 39% throughout the forecast period, fueled by the presence of a vast healthcare system and a rising prevalence of chronic diseases. The Asia Pacific market will see investment from governments. For instance, around USD 498 million investment by China in medical devices in 2024 demonstrates the commitment to patient safety in the region. In addition, the growth in the geriatric population is impacting demand in the region.
The acute care needleless connector market in China is undergoing rapid expansion due to the growth in patients needing IV therapy. According to the NHC, in 2023, there were over 1 million patients who were diagnosed with any disease/condition that required IV therapy. In 2024, Baxter worked with over 400 hospitals in China, which opened up market access by about 9%.

Companies Dominating the Acute Care Needleless Connector Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The acute care needleless connector market is extremely competitive. North American and European manufacturers such as BD and ICU Medical are most prevalent due to their technological advancements in products and regulatory compliance. In the Asia-Pacific region, disruptive companies like Terumo and Polymedicure can both leverage inexpensive production costs to enter emerging and growing markets like India. Sustainability trends are pushing some manufacturers in Europe, like Bionic, to implement green design strategies. The following table includes the top 15 global manufacturers, their estimated market share for 2024, and their associated country.
Company Name |
Country of Origin |
Market Share (2024) |
---|---|---|
Becton, Dickinson and Company (BD) |
USA |
18.5% |
ICU Medical, Inc. |
USA |
14.9% |
Baxter International Inc. |
USA |
12.2% |
B. Braun Melsungen AG |
Germany |
9.5% |
CareFusion Corporation (BD) |
USA |
7.8% |
Vygon SA |
France |
xx% |
RyMed Technologies, LLC |
USA |
xx% |
Nexus Medical, LLC |
USA |
xx% |
Medtronic |
Ireland |
xx% |
Terumo Corporation |
Japan |
xx% |
JMS Co., Ltd. |
Japan |
xx% |
Nipro Corporation |
Japan |
xx% |
Cardinal Health |
USA |
xx% |
Smiths Medical |
UK |
xx% |
myTemp BV |
Netherlands |
xx% |
Polymedicure Ltd. |
India |
xx% |
Harsoria Healthcare Pvt. Ltd. |
India |
xx% |
Bumi Sdn Bhd |
Malaysia |
xx% |
Yushin Medical Co., Ltd. |
South Korea |
xx% |
Bionic Medizintechnik GmbH |
Germany |
xx% |
Here are a few areas of focus covered in the competitive landscape of the acute care needleless connector market:
Recent Developments
- In September 2024, Becton, Dickinson and Company launched a new needle-free connector that demonstrated a decreased risk for central venous catheter intraluminal blood occlusions (CVC-IBO). This connector intends to improve clinical outcomes and patient safety.
- In October 2024, Shockwave Medical expanded its U.S. peripheral intravascular lithotripsy (IVL) portfolio with the introduction of the Shockwave E8 catheter. This catheter is designed to optimize treatment for patients with calcified peripheral artery disease.
- Report ID: 2970
- Published Date: Jun 09, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert